EW — Edwards Lifesciences Share Price
- $51.37bn
- $50.34bn
- $6.00bn
- 90
- 16
- 86
- 69
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 29.55 | ||
PEG Ratio (f) | 3.93 | ||
EPS Growth (f) | 8.13% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 7.22 | ||
Price to Tang. Book | 9.48 | ||
Price to Free Cashflow | 215.76 | ||
Price to Sales | 8.36 | ||
EV to EBITDA | 29.94 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 17.78% | ||
Return on Equity | 21.59% | ||
Operating Margin | 24.96% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 4,348 | 4,386.3 | 5,232.5 | 5,382.4 | 6,004.8 | 6,562.31 | 7,203.41 | 10.03% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +9.14 | +4.98 | +28.25 | +5.32 | +3.15 | +5.52 | +12.88 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. It sells products that are used to treat advanced cardiovascular disease in all regions.
Directors
- Michael Mussallem CHM (68)
- Scott Ullem CFO (55)
- Jean-Luc Lemercier CEX (64)
- Donald Bobo VPR (59)
- Daveen Chopra VPR (42)
- Catherine Szyman VPR (54)
- Huimin Wang VPR (64)
- Larry Wood VPR (55)
- Martha Marsh LED (72)
- Kieran Gallahue IND (57)
- Leslie Heisz IND (60)
- Paul LaViolette IND (63)
- Steven Loranger IND (69)
- Ramona Sequeira IND (55)
- Nicholas Valeriani IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 10th, 1999
- Public Since
- March 27th, 2000
- No. of Shareholders
- 7,599
- No. of Employees
- 19,800
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 602,600,000
- Address
- One Edwards Way, IRVINE, 92614
- Web
- https://www.edwards.com
- Phone
- +1 9492502500
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for EW
Edwards Lifesciences Corp Annual Shareholders Meeting
Q2 2024 Edwards Lifesciences Corp Earnings Release
Q3 2024 Edwards Lifesciences Corp Earnings Release
Similar to EW
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Agiliti
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
FAQ
As of Today at 01:07 UTC, shares in Edwards Lifesciences are trading at $85.25. This share price information is delayed by 15 minutes.
Shares in Edwards Lifesciences last closed at $85.25 and the price had moved by -3.01% over the past 365 days. In terms of relative price strength the Edwards Lifesciences share price has underperformed the S&P500 Index by -21.77% over the past year.
The overall consensus recommendation for Edwards Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Edwards Lifesciences does not currently pay a dividend.
Edwards Lifesciences does not currently pay a dividend.
Edwards Lifesciences does not currently pay a dividend.
To buy shares in Edwards Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $85.25, shares in Edwards Lifesciences had a market capitalisation of $51.37bn.
Here are the trading details for Edwards Lifesciences:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: EW
Based on an overall assessment of its quality, value and momentum Edwards Lifesciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Edwards Lifesciences is $95.48. That is 12% above the last closing price of $85.25.
Analysts covering Edwards Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of $2.76 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Edwards Lifesciences. Over the past six months, its share price has outperformed the S&P500 Index by +8.22%.
As of the last closing price of $85.25, shares in Edwards Lifesciences were trading +8.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Edwards Lifesciences PE ratio based on its reported earnings over the past 12 months is 29.55. The shares last closed at $85.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Edwards Lifesciences' management team is headed by:
- Michael Mussallem - CHM
- Scott Ullem - CFO
- Jean-Luc Lemercier - CEX
- Donald Bobo - VPR
- Daveen Chopra - VPR
- Catherine Szyman - VPR
- Huimin Wang - VPR
- Larry Wood - VPR
- Martha Marsh - LED
- Kieran Gallahue - IND
- Leslie Heisz - IND
- Paul LaViolette - IND
- Steven Loranger - IND
- Ramona Sequeira - IND
- Nicholas Valeriani - IND